Navigation Links
GSK Reports PROMACTA(R) (eltrombopag) Significantly Increased Platelet Counts and Reduced Bleeding in Long-Term Study of Patients With Chronic ITP
Date:12/6/2008

let count to 36,000/microliters, with median platelet levels subsequently ranging from 52,000 to 91,000/microliters for the remainder of the study, meeting the study's primary endpoint of odds of responding (platelets 50,000 to 400,000/microliters) during the six month treatment period. Patients receiving PROMACTA were eight times more likely to achieve an overall response of increased platelet counts of 50,000 to 400,000/microliters than those taking placebo (Odds ratio = 8.2; 99 percent CI [3.59, 18.73]; p < 0.001). In comparison to the placebo group, significantly fewer patients treated with PROMACTA had any bleeding or clinically significant (WHO Grades 2-4; p < 0.001) bleeding throughout the trial and more patients in the PROMACTA group (59 percent) stopped or reduced their simultaneous ITP medications than in the placebo group (32 percent; p = 0.016). In addition, during the treatment phase of the study, fewer patients in the PROMACTA arm (19 percent) required rescue therapy compared with those in the placebo arm (40 percent, p = 0.001).

The overall incidence of adverse events was similar between the PROMACTA (87 percent) and placebo groups (92 percent), which were mostly mild to moderate in severity. Headache was the most common adverse event in both groups (greater than or equal to 30 percent). Two corticosteroid-associated adverse events (dyspepsia and peripheral edema) were significantly less likely to occur in the PROMACTA group compared to the placebo group; however, a higher incidence of hepatobiliary laboratory abnormalities were reported in patients taking PROMACTA (13 percent) compared with those in the placebo group (7 percent). These abnormalities were not predictive of serious, drug-induced liver injury. One death was reported in the placebo group. There were no clinical or laboratory symptoms suggestive of bone marrow fibrosis in patients taking PROMACTA.

Additional GSK Data Presented at
'/>"/>

SOURCE GlaxoSmithKline
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Schering-Plough Reports Preladenant Meets Primary Endpoint in Phase II Dose-Finding Trial for Parkinsons Disease
2. GEN Reports on the Trend Toward Predictive Toxicogenomics
3. Vical Completes Enrollment and Reports Positive Interim Data in CMV Vaccine Phase 2 Trial
4. SCOLR Pharma, Inc. Reports Third Quarter 2008 Financial Results
5. Cadence Pharmaceuticals Reports Third Quarter 2008 Financial Results and Provides Clinical Development Programs Update
6. Bavarian Nordic Reports Successful Safety Data From Phase II Study With IMVAMUNE(R)
7. Rib-X Pharmaceuticals Reports Positive Phase 2 Study Results for Next Generation Oxazolidinone at 2008 ICAAC/IDSA Joint Meeting
8. Paratek Reports Positive Phase 2 Clinical Data on its New Antibiotic PTK 0796 in Late Breaker Presentation at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy
9. Novexel Reports Positive Phase II Trial Results With NXL103 in Adult Patients With Community Acquired Pneumonia
10. Genmab A/S - Company Announcement: Genmab Reports Results of Portfolio
11. Genaera Corporation Reports Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2015)... -- SeraCare Life Sciences, a leading partner to global ... AACC Annual Meeting today that it has signed ... biotechnology company that develops, markets and sells preanalytic ... ViveST™ allow sample collection, transport and storage in ... of the agreement, the two firms will jointly ...
(Date:7/27/2015)... July 27, 2015  The fairness of the proposed ... St. Jude Medical ("St. Jude") is the subject of ... shareholder rights law firm.  The investigation is focusing on ... law by the Board of Directors of THOR for ... July 22, 2015, the Company announced it had reached a ...
(Date:7/27/2015)... , July 20, 2015 ... has announced the addition of the "Cardiometabolic ... Afrezza,s discounted pricing is in line ... is critical to the product,s commercial appeal. However, ... prevent Afrezza from gaining a sizeable share of ...
Breaking Medicine Technology:SeraCare Life Sciences Announces Strategic Partnership with ViveBio to Enable Next Generation Preanalytic Products for the IVD Industry 2SeraCare Life Sciences Announces Strategic Partnership with ViveBio to Enable Next Generation Preanalytic Products for the IVD Industry 3WeissLaw LLP: Thoratec Corporation Acquisition By St. Jude Medical May Not Be In The Best Interest Of THOR Shareholders 2Cardiometabolic Drug News Issue - Afrezza Aggressive Pricing Strategy View Playing Out 2Cardiometabolic Drug News Issue - Afrezza Aggressive Pricing Strategy View Playing Out 3
... Motion Therapeutics, Inc. http://www.motiontherapeutics.com , the leading provider ... today announced that researchers at Samuel Merritt University and ... to study the effects of wearing a strategically weighted ... MS. This grant comes after the ...
... Argon Medical Devices, Inc. announced today that it ... LP ("Rex Medical") for exclusive global rights to market and ... device used in the prevention of Pulmonary Embolism (PE). ... to our product portfolio. This proven technology has rapidly become ...
Cached Medicine Technology:The Balance-Based Torso-Weighting® Treatment for Multiple Sclerosis Receives a NIH Recovery Act Grant 2Argon Medical Devices Announces Exclusive License and Distribution Agreement for Option™ Retrievable Inferior Vena Cava Filter 2Argon Medical Devices Announces Exclusive License and Distribution Agreement for Option™ Retrievable Inferior Vena Cava Filter 3
(Date:7/28/2015)... ... July 28, 2015 , ... ... that Schneider Electric has completed its upgrade and expansion of its ... with more than 170,000 employees in 134 countries supplying a wide range of ...
(Date:7/28/2015)... ... July 28, 2015 , ... ... biologics and biologic-device combination products for the treatment of bone disorders and conditions ... Patent No. 9,062,300 entitled "Fusion Proteins of Collagen Binding-Domain and Parathyroid Hormone". The ...
(Date:7/28/2015)... ... July 28, 2015 , ... A new Taiwanese study suggests ... are in the general population. Surviving Mesothelioma has just posted an article detailing ... at Taiwan’s National Health Research Institutes and three Taiwanese universities evaluated the health ...
(Date:7/28/2015)... MA (PRWEB) , ... July 28, 2015 , ... Women ... cancer. One reason is that cancer, heart attack, and stroke are treatable, but there ... thing individuals can do is to take part in a clinical trial, reports the ...
(Date:7/28/2015)... ... July 28, 2015 , ... Every summer, the public is reminded ... caution when lighting fireworks in their own neighborhoods. Unfortunately, according to a recent report ... 3, 2015 USA Today article " Eye Injuries Caused by Fireworks Doubled in Last ...
Breaking Medicine News(10 mins):Health News:Schneider Electric Amps Up Its Use of Kinetic Data’s Enterprise Request Management Software 2Health News:Schneider Electric Amps Up Its Use of Kinetic Data’s Enterprise Request Management Software 3Health News:Schneider Electric Amps Up Its Use of Kinetic Data’s Enterprise Request Management Software 4Health News:BiologicsMD, Inc. Announces Additional US Patent Issuance Covering Company’s Pipeline of Targeted Therapies 2Health News:New Findings Suggest Mesothelioma is Not the Only Cancer Threat for Shipbreakers, According to Surviving Mesothelioma 2Health News:Fight Alzheimer's By Taking Part in a Clinical Trial, From the July 2015 Harvard Women's Health Watch 2Health News:Fight Alzheimer's By Taking Part in a Clinical Trial, From the July 2015 Harvard Women's Health Watch 3Health News:Carlsbad Ophthalmologist Discusses Doubling of Fireworks Eye Injuries in Three Year Span 2Health News:Carlsbad Ophthalmologist Discusses Doubling of Fireworks Eye Injuries in Three Year Span 3
... (Jan. 17, 2008) Twenty research projects have been ... at the Argonne Leadership Computing Facility (ALCF) at Argonne ... competitively selected group of 55 scientific projects announced Thursday ... awards are made through the 2008 Innovative and Novel ...
... diagnostic tool to detect surface cancers quickly and ... calculate body composition has been developed by a ... from QUTs School of Physical and Chemical Sciences ... spectroscopy to diagnose cervical and skin cancers. , ...
... stroke and even death, study finds , , FRIDAY, ... to aspirin are four times more likely to suffer a ... says. , People who are aspirin-resistant have platelets -- the ... in the same way as platelets in people who respond ...
... Jan. 18 Cardiac Science,Corporation (Nasdaq: ... cardiac diagnosis,resuscitation, rehabilitation, and informatics products, announced ... its first responder units with,425 Powerheart(R) G3 ... (Logo: http://www.newscom.com/cgi-bin/prnh/20050913/SFTU139LOGO ), "Like first ...
... Farm Safety 4 Just Kids Founder, Adams, Reaches Finals of 6th Annual Volvo ... Celebrity Judges Will Select and Unveil Top Four Winners March 19 at Volvo,for life ... ... Life, IRVINE, Calif., Jan. 18 For the past ...
... Jan. 18 /PRNewswire-FirstCall/ - QLT Inc. (NASDAQ: QLTI;,TSX: ... reduction in its,overall headcount affecting approximately 115 people ... U.S. subsidiaries, including members,of its management team., ... undertaken by the,Company as part of its strategic ...
Cached Medicine News:Health News:Argonne's Blue Gene/P to host large cadre of INCITE researchers 2Health News:Argonne's Blue Gene/P to host large cadre of INCITE researchers 3Health News:Argonne's Blue Gene/P to host large cadre of INCITE researchers 4Health News:Argonne's Blue Gene/P to host large cadre of INCITE researchers 5Health News:Argonne's Blue Gene/P to host large cadre of INCITE researchers 6Health News:Argonne's Blue Gene/P to host large cadre of INCITE researchers 7Health News:Cardiac Science Completes Deployment of AEDs With Los Angeles County Fire Department 2Health News:Cardiac Science Completes Deployment of AEDs With Los Angeles County Fire Department 3Health News:America Selects Earlham Resident Marilyn Adams as One of the Nation's Top Hometown Heroes 2Health News:America Selects Earlham Resident Marilyn Adams as One of the Nation's Top Hometown Heroes 3Health News:America Selects Earlham Resident Marilyn Adams as One of the Nation's Top Hometown Heroes 4Health News:America Selects Earlham Resident Marilyn Adams as One of the Nation's Top Hometown Heroes 5Health News:QLT reduces workforce as first step in its strategic restructure 2Health News:QLT reduces workforce as first step in its strategic restructure 3
The ultimate ultrasound system for clinical ophthalmologists....
The Ultrasonic BioMicroscope (UBM P40) provides the highest ultrasound resolution for imaging....
EchoScan US-3300 takes accurate axial length and corneal thickness measurements in either automatic or manual modes. It is available in a single configuration or in combination with the A scan for ma...
... eye. Whether used as part of ... independently to accommodate a specific scanning ... to accommodate maximizing the image resolution. ... tonometer-mounted, hand-held and immersion techniques. Unique ...
Medicine Products: